Amgen 10-Qquarter ended 2026-06-30

Executive Summary

Amgen delivered Q2 revenue growth of 9.5%, driven by higher product volumes and newer medicines, while biosimilar competition and lower net prices eroded established brands. Earnings rose faster than sales, but part of that improvement reflects lower acquisition-related amortization and an $800M impairment in the prior-year comparison, rather than operating growth alone. H1 cash generation funded higher capital spending and dividends, while new borrowing increased the debt balance and no shares were repurchased. For investors, the central question is whether newer products can outgrow losses in Prolia and XGEVA amid pricing pressure, a potential TAVNEOS withdrawal and substantial tax litigation.

Key Financial Highlights

• Earnings quality: H1 OCF rose from $3.67B, partly because H1 2025 included a $1.8B final repatriation-tax payment. H1 FCF rose from $2.89B even as capital expenditures increased from $780M for plant construction and capacity expansion.
• Comparability: H1 2025 included an $800M Otezla intangible-asset impairment. H1 2026 finite-lived intangible amortization fell to $1.8B from $2.3B; those accounting effects are not product-sales growth.
• Investments: Amgen’s BeOne Medicines stake generated a $357M unrealized H1 loss vs a $1.1B gain a year earlier, tempering the improvement in operating income.
• Capital allocation: Amgen paid $2.72B in H1 dividends and repurchased no shares; shares outstanding rose to 540.6M from 538.8M at year-end. It issued $4.0B of notes and retained an undrawn $4.0B revolving facility.

Business Developments

H1 product-sales growth reflected 9% higher volume, partly offset by lower net prices. Q2 growth in Repatha ($953M from $696M), EVENITY ($714M from $518M) and TEZSPIRE ($486M from $342M) demonstrates the portfolio’s capacity to replace mature-brand sales; UPLIZNA and IMDELLTRA/IMDYLLTRA also expanded rapidly. European authorization in June for IMDYLLTRA in eligible small cell lung cancer patients adds a commercial opportunity.

That replacement is not yet assured. Q2 Prolia sales fell to $759M from $1.12B and XGEVA to $352M from $532M as biosimilars entered following patent expirations. Otezla and ENBREL also declined amid price, generic and reimbursement pressure. Management expects volume growth to remain partly offset by lower net prices through the rest of 2026.

Amgen increased H1 R&D spending to $3.59B from $3.23B, principally for later-stage programs including MariTide. It plans ≈$2.6B of 2026 capital-project investment to expand manufacturing capacity: a commitment to future supply that raises near-term spending and execution demands.

Risk Assessment

• Pricing and biosimilars: Prolia and XGEVA erosion coincides with a significantly lower Medicare-set ENBREL price effective 1/1/2026; Otezla’s set price begins 1/1/2027, increasing pressure on mature-product profitability.
• TAVNEOS authorization and valuation: After serious liver-injury reports, the Food and Drug Administration proposed withdrawing approval; an adverse outcome could remove U.S. sales and impair the $2.4B developed-technology asset.
• Tax litigation: The Internal Revenue Service seeks $3.6B of additional tax plus interest for 2010–2012 and $5.1B plus interest and $2.0B of penalties for 2013–2015, subject to potential offsets; an adverse decision could substantially exceed accrued amounts.
• Debt and refinancing: Debt carrying value rose to $57.3B, while H1 net interest expense was $1.33B; leverage limits flexibility if product erosion or litigation consumes cash.
• Supply and execution: Single-source contract manufacturers, including one in Israel for KRYSTEXXA drug substance, expose sales to disruption; new manufacturing capacity can take years to qualify.
• Cybersecurity and service providers: Prior third-party incidents disrupted patient-support and payment processes; a more severe outage or data breach could interrupt sales and create legal costs.

Strategic Outlook and Investor Actionables

Amgen is investing in newer medicines and manufacturing to offset mature-brand erosion. The investment case strengthens if volume-led launches sustain growth without further margin compression; it weakens if pricing, biosimilars or regulatory outcomes absorb those gains.

• Portfolio replacement: Monitor Repatha, EVENITY, TEZSPIRE and IMDELLTRA/IMDYLLTRA sales growth against the combined decline in Prolia and XGEVA.
• Margin and cash conversion: Monitor product-sales volume vs net-price effects, operating margin and OCF after elevated capital expenditures; separate recurring performance from amortization changes.
• Binary exposures: Watch the TAVNEOS hearing and asset assessment, plus the tax-case decision expected no earlier than late 2026 or early 2027.